Breast Cancer

Sara A. Hurvitz, MD, discusses the evolving treatment paradigm in HER2-positive breast cancer, ongoing research in the space, and developments in the treatment of triple-negative breast cancer.

The treatment of patients with breast cancer is making noteworthy strides in several clinical settings, with recent trial results showing overall survival improvements for advanced and metastatic disease.

Capivasertib plus fulvestrant generated a statistically and clinically significant improvement in progression-free survival in select patients with hormone receptor–positive, HER2-low or -negative, locally advanced or metastatic breast cancer.

Camizestrant led to a statistically significant improvement in progression-free survival compared with fulvestrant in postmenopausal patients with estrogen receptor–positive, locally advanced, or metastatic breast cancer who were previously treated with endocrine therapy for advanced disease.

Naoto T. Ueno, MD, PhD, FACP, discusses patient-reported outcomes with fam-trastuzumab deruxtecan-nxki (Enhertu) in hormone receptor (HR)–positive/HER2-low metastatic breast cancer.

Jeannie Shen, MD, discussed the shifts in surgical practice for patients with breast cancer, the need for a multidisciplinary approach to optimize treatment for individual patients, and ongoing efforts at Huntington Hospital and Cedars-Sinai to increase awareness and improve care for these patients.

Centering discussion on antibody-drug conjugates in HR+ metastatic breast cancer, panelists consider the selection and use of these agents in practice.

Centering their discussion on the HER2 low setting of HR+ metastatic breast cancer, medical oncologists review data behind trastuzumab deruxtecan therapy.

Yuan Yuan, MD, PhD, discusses the role immune checkpoint inhibitors have played in the treatment of triple-negative breast cancer, ongoing efforts to investigate the role of immunotherapy in breast cancer, and the work Cedars-Sinai is conducting to promote breast cancer awareness.

Megan Kruse, MD, discusses the evolving treatment landscape in HR-positive, HER2-negative breast cancer, how the approval of fam-trastuzumab deruxtecan-nxki has affected sequencing choices in HER2-positive disease, and the importance of addressing racial disparities in breast cancer care.

Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.

The addition of palbociclib to adjuvant endocrine therapy (ET) failed to improve invasive disease-free survival over ET alone in patients with estrogen receptor–positive, HER2-negative early breast cancer.

Treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.

Amit Jain, MD, discusses the benefit of CDK7 inhibitors in hormone receptor–positive breast cancers.

Shared insight on appropriate treatment options for patients with HR+ metastatic breast cancer following progression on CDK4/6 inhibitors.

Expert panelists consider when it is appropriate to continue the use of CDK4/6 inhibitors beyond progression in HR+ metastatic breast cancer.

Kevin Kalinsky, MD, MS, discusses the role of chemotherapy with ovarian function suppression and hormonal therapy for premenopausal patients with HR–positive/HER2-negative breast cancer.

Abemaciclib produced a clinically manageable safety profile in patients with hormone receptor–positive, HER2-negative, early breast cancer or advanced breast cancer, and dose reductions were found to effectively mitigate discontinuation.

Shared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.

Before closing out their discussion on HER2+ gastric cancer, experts review clinical trials investigating other novel ADC agents in this setting.

The FDA has accepted and granted priority review to a supplemental biologics license application for sacituzumab govitecan for the treatment of with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer after endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.

Megan Kruse, MD, discusses the real-world effects of the phase 2 MAINTAIN trial on treatment in advanced hormone receptor–positive, HER2-negative breast cancer.

Sequencing complexities with chemotherapy-based regimens in metastatic breast cancer pose unique challenges for valuebased decision-making in routine practice.

Kelly Hewitt, MD, discusses treatment considerations for breast conservation vs mastectomy in breast cancer.

In the context of recent clinical trials, experts share their perspective on the selection and use of CKD4/6 inhibitor therapy in patients with HR+ metastatic breast cancer.